These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31323137)

  • 21. Cost savings from dose rounding of biologic anticancer agents in adults.
    Winger BJ; Clements EA; DeYoung JL; O'Rourke TJ; Claypool DL; Vachon S; VanDyke TH; Zimmer-Young J; Kintzel PE
    J Oncol Pharm Pract; 2011 Sep; 17(3):246-51. PubMed ID: 20332175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Financial impact of oral chemotherapy wastage on society and the patient.
    Monga V; Meyer C; Vakiner B; Clamon G
    J Oncol Pharm Pract; 2019 Jun; 25(4):824-830. PubMed ID: 29575989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outpatient cancer drug costs: changes, drivers, and the future.
    Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
    Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parenteral cytotoxic drug wastage at a tertiary hospital in Kuala Lumpur: How much and why?
    Ang ZY; Cheah KY; Abdullah NB; Samsuri SB; Lee SH; Yem AW; Sriraman MA
    J Oncol Pharm Pract; 2020 Sep; 26(6):1306-1317. PubMed ID: 31810422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating cost savings in cytotoxic leftover management: A prospective study of vial sharing and dose rounding techniques in the Moroccan National Institute of Oncology.
    El Baraka S; Cherif Chefchaouni A; Bourdaime A; Ouedraogo JM; Shytry O; Belahcen MJ; Rahali Y
    J Oncol Pharm Pract; 2024 Oct; 30(7):1152-1159. PubMed ID: 37728162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficiency of oncologic treatments for solid tumours in Spain].
    Oyagüez I; Frías C; Seguí MÁ; Gómez-Barrera M; Casado MÁ; Queralt Gorgas M
    Farm Hosp; 2013; 37(3):240-59. PubMed ID: 23789801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of antineoplasic chemotherapy administered at home or in hospitals.
    Remonnay R; Devaux Y; Chauvin F; Dubost E; Carrère MO
    Int J Technol Assess Health Care; 2002; 18(3):508-19. PubMed ID: 12391944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions.
    Khandelwal N; Duncan I; Ahmed T; Rubinstein E; Pegus C
    J Natl Compr Canc Netw; 2012 May; 10(5):618-25. PubMed ID: 22570292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital.
    Matsuo K; Nomura H; Uchiyama M; Miyazaki M; Imakyure O
    BMC Health Serv Res; 2020 Nov; 20(1):1017. PubMed ID: 33167996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of pricing strategy on the costs of oral anti-cancer drugs.
    Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
    Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A preliminary analysis of the reduction of chemotherapy waste in the treatment of cancer with centralization of drug preparation.
    Hyeda A; Costa ES
    Rev Assoc Med Bras (1992); 2015 Aug; 61(4):368-74. PubMed ID: 26466220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hospital information systems ineffectiveness in costing ambulatory chemotherapy in pulmonary oncology].
    Thomas P; Raholimina V; Ferri-Dessens RM; Pibarot M; Penot Ragon C; Gregoire R; Kleisbauer JP
    Rev Mal Respir; 2000 Jun; 17(3):659-63. PubMed ID: 10951960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a method to determine the cost of breast cancer treatment with chemotherapy at Groote Schuur Hospital, Cape Town, South Africa.
    Guzha NT; Thebe T; Butler N; Valodia PN
    S Afr Med J; 2020 Mar; 110(4):296-301. PubMed ID: 32657741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cost of medications in the oncology sector in the context of health economics].
    Walter E; Batista A
    Wien Med Wochenschr; 2008; 158(7-8):227-33. PubMed ID: 18500477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost analysis of in-patient cancer chemotherapy at a tertiary care hospital.
    Wani MA; Tabish SA; Jan FA; Khan NA; Wafai ZA; Pandita KK
    J Cancer Res Ther; 2013; 9(3):397-401. PubMed ID: 24125973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes.
    Hatswell AJ; Porter JK
    Appl Health Econ Health Policy; 2019 Jun; 17(3):391-397. PubMed ID: 30520000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases.
    Sodré SL; Barbosa IAF; Pacheco IE; Ferreira FQT; David MA; Nascimento MA; Arieta CEL; Vasconcellos JPC
    BMC Public Health; 2019 Sep; 19(1):1252. PubMed ID: 31510981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implications of dose rounding of chemotherapy to the nearest vial size.
    Dooley MJ; Singh S; Michael M
    Support Care Cancer; 2004 Sep; 12(9):653-6. PubMed ID: 14986078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
    Prasad V; Mailankody S
    Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.